Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience

Mayo Clinic

Status: Invitation-only

Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Treatments: Other: Non-Interventional Study

Study type: Observational

Funder types: Other

Identifiers

NCT07307833

22-009510 (Other Identifier)

NCI-2025-08558 (Registry Identifier)

MC250709 (Other Identifier)

Details and patient eligibility

About

This study evaluates the impact of immunotherapy on balance in patients receiving immunotherapy as part of their standard of care.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age at screening
• Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab)

Exclusion criteria

• Concurrent chemotherapy

Trial design

50 participants in 1 patient group

Observational

Description:

Patients undergo vestibular function testing with video head impulse testing, sinusoidal harmonic acceleration testing, and pure tone audiometry and complete questionnaires throughout the study.

Treatment:

Other: Non-Interventional Study